IBI389
IBI389 is an anti-Claudin18.2 × CD3 bispecific antibody. IBI389 binds CD3 and Claudin18.2 to engage T cells, induce immune synapse formation, and redirect T cell killing of Claudin18.2-positive tumors. IBI389 increases intratumoral CD3+/CD8+ T cells, an immuno-inflammatory phenotype, shortens tumor-T cell distance, compensatorily increases regulatory T cells, and elevates IL-2/IFN-γ; IL-4/IL-10/IL-17A/TNF-α are decreased. IBI389 can be used in gastric cancer-related research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Species Reactivity
Human
IC50 & Target
[1]|
IL-10 |
IL-17A |
IL-4 |
IL-2 |
TNF-α |
In Vivo
IBI389 (1-10 mg/kg; i.v.; every 2 weeks) suppresses tumor growth and increases intratumoral CD3+ T-cell density in the KPC pancreatic cancer model, and combination with PD-1 blockade provides the strongest tumor inhibition[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Target
Claudin18.2 & CD3
Conjugated
Unconjugated
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[IBI389]
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
IBI389 Related Classifications
HY-P992540 Related Classifications
Powered by Bioz